We present the case of an 18-year-old male with recurrent Hodgkin’s lymphoma who developed bilateral intraocular inflammation 47 days after initiating nivolumab. Examination revealed bilateral chorioretinitis and papillitis with subretinal fluid in the left eye. Nivolumab was discontinued, and combined oral and topical corticosteroid therapy was initiated, leading to the resolution of symptoms 37 days after presentation. Nivolumab-induced ocular inflammation is a rare but significant immune-related adverse event in patients receiving immune checkpoint inhibitor therapy. To our knowledge, this is the youngest reported case of posterior uveitis associated with nivolumab and the youngest patient with Hodgkin’s lymphoma to develop this complication following immunotherapy. Although previously documented in older populations, its occurrence in an adolescent highlights the need for routine ophthalmic evaluations in all individuals undergoing this treatment. These findings suggest that early recognition, prompt cessation of the offending agent, and timely management with both oral and topical corticosteroids can prevent long-term visual impairment. With the expanding use of immune checkpoint inhibitors across all populations, proactive ophthalmic monitoring will be essential for preserving long-term ocular health.
- Open Access
- Case Report
Bilateral Chorioretinitis and Neurosensory Retinal Detachment after Nivolumab Therapy in a Young Patient with Hodgkin Lymphoma
- Jacob Larsen *,
- Garrett Nix,
- Jennifer Jung,
- Rebecca G. Edwards Mayhew
Author Information
Received: 18 Feb 2026 | Revised: 21 Jun 2026 | Accepted: 02 Jul 2026 | Published: 24 Jul 2026
Abstract
Keywords
immune checkpoint inhibitor | intraocular inflammation | subretinal fluid | Hodgkin’s lymphoma | corticosteroids
References
- 1.
Ansell, S.M. Nivolumab in the Treatment of Hodgkin Lymphoma. Clin. Cancer Res. 2017, 23, 1623–1626.
- 2.
Dalvin, L.A.; Shields, C.L.; Orloff, M.; Sato, T.; Shields, J.A. Checkpoint inhibitor immune therapy: Systemic Indications and Ophthalmic Side Effects. Retina 2018, 38, 1063–1078.
- 3.
Bodaghi, B.; Cassoux, N.; Wechsler, B.; Hannouche, D.; Fardeau, C.; Papo, T.; Huong, D.L.; Piette, J.C.; LeHoang, P. Chronic severe uveitis: Etiology and visual outcome in 927 patients from a single center. Medicine 2001, 80, 263–270.
- 4.
Bitton, K.; Michot, J.M.; Barreau, E.; Lambotte, O.; Haigh, O.; Marabelle, A.; Voisin, A.L.; Mateus, C.; Remond, A.L.; Couret, C.; et al. Prevalence and Clinical Patterns of Ocular Complications Associated with Anti-PD-1/PD-L1 Anticancer Immunotherapy. Am. J. Ophthalmol. 2019, 202, 109–117.
- 5.
Sun, M.M.; Levinson, R.D.; Filipowicz, A.; Anesi, S.; Kaplan, H.J.; Wang, W.; Goldstein, D.A.; Gangaputra, S.; Swan, R.T.; Sen, H.N.; et al., Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul. Immunol. Inflamm. 2020, 28, 217–227.
- 6.
Obata, S.; Saishin, Y.; Teramura, K.; Ohji, M. Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. Case Rep. Ophthalmol. 2019, 10, 67–74.
- 7.
Yilmaz Tugan, B.; Ozkan, B.; Sonmez, O. Recurrent Episodes with Serous Retinal Detachment and Anterior Uveitis in a Patient Using Nivolumab (Anti-PD-1 Antibody) Therapy: A case report and literature review. Semin. Ophthalmol. 2021, 36, 794–799.
- 8.
Miyamoto, R.; Nakashizuka, H.; Tanaka, K.; Wakatsuki, Y.; Onoe, H.; Mori, R.; Kawamura, A. Bilateral multiple serous retinal detachments after treatment with nivolumab: A case report. BMC Ophthalmol. 2020, 20, 221.
- 9.
Seagen Inc. ADCETRIS® (brentuximab vedotin); [package insert]; Seagen Inc.: Bothell, WA, USA, 2025. Available online: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f (accessed on 10 February 2026).
- 10.
Liu, M.; Ren, K.; Ai, P.; Zou, L. Insights into uveitis from Brentuximab vedotin in refractory Hodgkin’s lymphoma: A case report and brief review. Front. Oncol. 2024, 14, 1419145.
- 11.
Antman, G.G.; Abrahami, G.; Berliner, O.; Erlich, R.; Reich, E.; Kramer, M. Uveitis induced by brentuximab vedotin-a novel adverse response to antibody-drug conjugate therapy. Clin. Oncol. Case Rep. 2021, 4, 10-1007.
- 12.
Therssen, S.; Meers, S.; Jacob, J.; Schauwvlieghe, P.P. Brentuximab vedotin induced uveitis. Am. J. Ophthalmol. Case Rep. 2022, 26, 101440.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com